Format

Send to

Choose Destination
Ann Rheum Dis. 2019 Feb 12. pii: annrheumdis-2019-215108. doi: 10.1136/annrheumdis-2019-215108. [Epub ahead of print]

Response to: 'Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis' by Cutolo et al.

Author information

1
Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
2
Institute of Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.
3
IONTAS Ltd, Cambridge, UK.
4
Rheumatology Research Group, School of Immunity and Infection, Birmingham, UK.
5
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
6
Nascient, Cambridge, UK.
7
Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
8
Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
9
Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK kim.midwood@kennedy.ox.ac.uk.

KEYWORDS:

early rheumatoid arthritis; inflammation; treatment

Conflict of interest statement

Competing interests: MRD, PS, KP, AK-V and JLM are employed by IONTAS. EC and PH are employed by Nascient. KSM is a founder and director of Nascient Ltd.AF has received research funding from Roche and Pfizer. KR has received research funding from Abbvie and Pfizer and honoraria/consultancy fees from Lilly, BMS,UCB, Pfizer, Janssen and Roche Chugai. JLM is currently funded by Roche Holding AG. BDM was partly supported by the SGC, which is a registered charity (number1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim,Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute (OGI-055), Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD grant no. 115766), Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research,Innovation and Science (MRIS), Pfizer, Sao Paulo Research Foundation – FAPESP, Takeda and Wellcome (106169/ZZ14/Z).

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center